Clinical Trial Platform

The Clinical Trial Platform is designed specifically for care providers, enabling them to find suitable clinical trials more efficiently, assess patients earlier, and simplify trial operations. It leverages a broad network and advanced technology to optimize trial sourcing, enhance patient participation, and maintain a focus on patient care.

Maximize Your Portfolio

Enhance the value of your study portfolio by intelligently analyzing patient populations and performance metrics. Select the most suitable studies for your institution from a vast array of potential opportunities.

• Source Smarter: Collaborate directly with sponsors and utilize technology, such as large language models (LLMs), to make informed trial decisions. Systematically evaluate new trial opportunities to ensure they align with your organization and patient demographics.
• Refine Your Portfolio: Gain a comprehensive view of your research portfolio. Identify opportunities for patients not yet enrolled and analyze your clinical trial portfolio's performance against expected enrollment rates. Prioritize new, impactful trial opportunities that align with your current research focus.

Optimize Execution

Accelerate study start-up, enrollment, and data collection while reducing administrative burdens through seamless platform integration that automates much of the study execution process.

• Launch Faster: Overcome legal and administrative delays with standardized processes and support in engaging with sponsors and CROs.
• Accelerate Enrollment: Utilize AI-driven capabilities to match, pre-screen, and consent patients swiftly, supported by experienced clinical staff.
• Automate Data Entry: Improve data quality by automatically populating electronic case report forms (eCRFs) with integrated eSource data from your systems.

Identify the most trial-eligible patients quickly and guide them to trial options during their next appointment. Discover how Paradigm Health assisted Altru Health System in increasing clinical trial enrollment from 4% to 11%.